Ozempic may be reshaping the brain, scientists say

A team at the University of Colorado Anschutz, led by assistant professor Allison Shapiro, discovered unexpected brain changes in 13 teens and young women with a hormonal disorder after they were treated with GLP-1 drugs. Brain scans showed a rapid increase in connections within the salience network, which governs attention, though researchers admit they do not yet understand the implications. Originally developed to regulate hunger, blood sugar, and weight, GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound are now among the most widely prescribed medications worldwide. Beyond their metabolic effects, scientists are exploring whether these drugs influence addiction, cognition, neurodegeneration, and even motivation and pleasure. Some users report side effects such as brain fog and emotional flattening, including reduced pleasure and diminished interest in hobbies. The study reflects a broader shift in medical research, recognizing the deep connection between brain and physical health. While exercise and nutrition are known to improve cognitive function, the neurological effects of GLP-1 drugs remain unclear. Researchers are still determining whether these medications act directly on the brain or indirectly through metabolic improvements. The hormones targeted by GLP-1 drugs extend beyond the stomach, with receptors present in the heart and brain. However, their large molecular structure raises questions about how much can cross the blood-brain barrier. Scientists are investigating whether the drugs’ effects on neural networks stem from direct brain interaction or secondary benefits like reduced inflammation and stress relief. Early findings suggest potential risks, including altered reward and motivation systems, which could blur the line between suppressing harmful impulses and fundamentally changing personality. As millions continue to use these medications, further research is needed to fully understand their long-term neurological impact.